Rheumatoid Arthritis Consultation

Treatment for Rheumatoid Arthritis has improved greatly over the last few years. Biological disease modifying anti-rheumatic disease medications (Biological DMARDs) that have been used in the United States and Europe for over 10 years and become available in Japan since 2003.

We are the only establishment in Japan with two rheumatoid connective tissue disease specialists board certified both in the United States and Japan. We continually strive to provide the best global standard treatments possible for early rheumatoid arthritis. Our goal is to provide early diagnosis and treatment, so we try to accommodate patients who may possibly have rheumatoid arthritis as soon as we possibly can.

We also proactively provide consultation for psoriatic arthritis and ankylosing spondylitis, which are very similar to rheumatoid arthritis.

We have extensive experience in using biological drugs including infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), tocilizumab (Actemra), abatacept (Orencia), Golimumab (Simponi), Certolizumab (Cimzia), and anakinra (Kineret).

Connective Tissue Disease

Our treatment outcomes for systematic lupus erythematous (SLE) and polymyositis/dermatomyositis have been actively presented at overseas conferences. We also have treatment experience in specified intractable diseases such as systemic sclerosis (scleroderma), Wegner's granulomatosis (GPA), and microscopic polyangiitis (MPA). Connective tissue disease is a systematic illness that may be accompanied by systemic complications such as glomerulonephritis, interstitial pneumonia, and pulmonary hypertension. Our department also provides integrative and specialized treatment for these complications.

We have extensive experience using a variety of immunosuppressants including tacrolimus (Prograf), mycophenolate mofetil (CellCept), mizoribine (Bredinin), cyclophosphamide (Endoxan), azathioprine (Imuran), cyclosporine (Neoral), methotrexate (Rheumatrex) and rituximab (Rituxan) as well as sildenafil (Revatio) and bosentan (Tracleer) for pulmonary hypertension.

Juvenile Rheumatoid Arthritis, Connective Tissue Disease

We are one of the few facilities in Japan with full-time Juvenile Rheumatoid Arthritis specialists. Taking into account the importance of growth characteristics particular to children as well as social background, we provide professional treatment using biological DMARDs (Actemra, Enbrel, Humira) with dramatic progress being achieved in the last several years.

Disease and Expertise

• Systematic Lupus Erythematous and Lupus Nephritis
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Polymyositis/Dermatomyositis and Interstitial Pneumonia
• Systemic Sclerosis and Pulmonary Hypertension
• Mixed Connective Tissue Disease
• Behcet's Disease
• Vasculitis (Takayasu Disease, Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener's Granulomatosis)
• Juvenile Idiopathic Arthritis (Juvenile Arthritis)
• Connective Tissue Diseases in Children
• Anaphylaxis